Literature DB >> 28004135

Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.

Peter Lin1,2,3, Myo Min4,5,6, Mark Lee4,5, Lois Holloway4,7,5,6, Dion Forstner4,5,6, Victoria Bray5, Allan Fowler5.   

Abstract

PURPOSE: To evaluate the prognostic utility of nodal metabolic parameters derived from FDG PET/CT performed before radiotherapy (prePET) and during the third week of radiotherapy (iPET) in patients with mucosal primary head and neck squamous cell carcinoma (MPHNSCC).
METHODS: This analysis included 75 patients with newly diagnosed locally advanced node-positive MPHNSCC treated with radical radiotherapy and concurrent systemic therapy who underwent prePET and iPET: N1 11 patients, N2a 38, N2b 12, N2c 9, N3 5. The median follow-up was 28 months (9 - 70 months). The maximum and mean standardized uptake values (SUVmax and SUVmean), metabolic tumour volume (MTV) and total lesional glycolysis (TLG) of the index lymph node (node with the highest TLG) and the combined total lymph nodes, and their percentage reductions on iPET were determined, and the results were correlated with 3-year Kaplan-Meier locoregional, regional and distant metastatic failure-free survival (FFS), disease-free survival (DFS) and overall survival (OS). Optimal cut-off values were derived from receiver operating characteristic curves. Cox regression univariate and multivariate analyses with clinical covariates were performed.
RESULTS: Based on assessment of residual nodal metabolic burden during treatment, the iPET index node SUVmean (optimal cut-off value 2.95 g/ml) and the total node SUVmean (optimal cut-off value 3.25) were the best independent predictors of outcome in the multivariate analysis: index node SUVmean for DFS and OS p = 0.033 and 0.003, respectively, and the total node SUVmean for locoregional FFS, DFS and OS p = 0.028, 0.025 and 0.014, respectively. Based on the assessment of response rates during treatment, a reduction of more than 50 % in the total node TLG was the best biomarker for locoregional and regional FFS, DFS and OS in the multivariate analysis (p = 0.001, 0.016, 0.001 and 0.004, respectively), and reduction in the total node MTV for locoregional FFS, DFS and OS (p = 0.026, 0.003 and 0.014, respectively). There were no significant correlations between oncological outcomes and prePET nodal parameters.
CONCLUSION: We demonstrated that the index node and total node SUVmean on iPET and a reduction of more than 50 % in MTV and TLG are useful imaging biomarkers, and can potentially identify those patients with MPHNSCC who have a high risk of locoregional metastatic failure and death.

Entities:  

Keywords:  FDG PET/CT; Imaging biomarkers; Mucosal primary head and neck squamous cell carcinoma; Positron emission tomography; Radiotherapy

Mesh:

Substances:

Year:  2016        PMID: 28004135     DOI: 10.1007/s00259-016-3584-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy.

Authors:  Sandro V Porceddu; David I Pryor; Elizabeth Burmeister; Bryan H Burmeister; Michael G Poulsen; Matthew C Foote; Benedict Panizza; Scott Coman; David McFarlane; William Coman
Journal:  Head Neck       Date:  2011-01-14       Impact factor: 3.147

2.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

Review 3.  Identifying patients who may benefit from adaptive radiotherapy: Does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help?

Authors:  Charlotte L Brouwer; Roel J H M Steenbakkers; Johannes A Langendijk; Nanna M Sijtsema
Journal:  Radiother Oncol       Date:  2015-06-17       Impact factor: 6.280

4.  Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.

Authors:  Maria Hentschel; Steffen Appold; Andreas Schreiber; Nasreddin Abolmaali; Andrij Abramyuk; Wolfgang Dörr; Joerg Kotzerke; Michael Baumann; Klaus Zöphel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-25       Impact factor: 9.236

5.  Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.

Authors:  M Min; P Lin; M Lee; I Ho Shon; M Lin; D Forstner; M T Tieu; A Chicco; V Bray; A Fowler
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-01-11       Impact factor: 4.126

6.  Can "early" and "late"18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?

Authors:  Paola Castaldi; Vittoria Rufini; Francesco Bussu; Francesco Miccichè; Nicola Dinapoli; Rosa Autorino; Mariaelena Lago; Eugenio De Corso; Giovanni Almadori; Jacopo Galli; Gaetano Paludetti; Alessandro Giordano; Vincenzo Valentini
Journal:  Radiother Oncol       Date:  2012-03-27       Impact factor: 6.280

7.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.

Authors:  Trang H La; Edith J Filion; Brit B Turnbull; Jackie N Chu; Percy Lee; Khoa Nguyen; Peter Maxim; Andy Quon; Edward E Graves; Billy W Loo; Quynh-Thu Le
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-14       Impact factor: 7.038

8.  Assessment of serial multi-parametric functional MRI (diffusion-weighted imaging and R2*) with (18)F-FDG-PET in patients with head and neck cancer treated with radiation therapy.

Authors:  Myo Min; Mark T Lee; Peter Lin; Lois Holloway; Dj Wijesekera; Dinesh Gooneratne; Robba Rai; Wei Xuan; Allan Fowler; Dion Forstner; Gary Liney
Journal:  Br J Radiol       Date:  2015-12-09       Impact factor: 3.039

9.  The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.

Authors:  Angela van Baardwijk; Christophe Dooms; Robert Jan van Suylen; Erik Verbeken; Monique Hochstenbag; Cary Dehing-Oberije; Dennis Rupa; Silvia Pastorekova; Sigrid Stroobants; Ulrich Buell; Philippe Lambin; Johan Vansteenkiste; Dirk De Ruysscher
Journal:  Eur J Cancer       Date:  2007-05-23       Impact factor: 9.162

10.  Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer.

Authors:  K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-02-01       Impact factor: 7.038

View more
  7 in total

1.  PET-based prognostic survival model after radiotherapy for head and neck cancer.

Authors:  Joël Castelli; A Depeursinge; A Devillers; B Campillo-Gimenez; Y Dicente; J O Prior; E Chajon; F Jegoux; C Sire; O Acosta; E Gherga; X Sun; B De Bari; J Bourhis; R de Crevoisier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-21       Impact factor: 9.236

2.  Quantitative parameters derived from 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging can accurately estimate the histologic grade of hypopharyngeal squamous cell carcinoma preoperatively.

Authors:  Zhaoting Meng; Lingyu Zhang; Caiyun Huang; Yingshi Piao; Xiaohong Chen; Junfang Xian
Journal:  Neuroradiology       Date:  2022-09-19       Impact factor: 2.995

3.  A predictive model for treatment response in patients with locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: based on SUVmean and NLR.

Authors:  Chunsheng Wang; Kewei Zhao; Shanliang Hu; Yong Huang; Li Ma; Yipeng Song; Minghuan Li
Journal:  BMC Cancer       Date:  2020-06-10       Impact factor: 4.430

Review 4.  What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis.

Authors:  Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-09       Impact factor: 9.236

5.  Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients.

Authors:  Suzy Kim; Sowon Oh; Jin Soo Kim; Yu Kyeong Kim; Kwang Hyun Kim; Do Hoon Oh; Dong-Han Lee; Woo-Jin Jeong; Young Ho Jung
Journal:  Radiat Oncol J       Date:  2018-06-29

6.  Utility and limitations of metabolic parameters in head and neck cancer: finding a practical segmentation method.

Authors:  Jefferson Rijo-Cedeño; Jorge Mucientes; Ithzel María Villarreal; Ana Royuela; Patricia García Vicente; José Ramón García-Berrocal
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-05-02       Impact factor: 3.236

Review 7.  Predicting response to radiotherapy in tumors with PET/CT: when and how?

Authors:  Li-Fang Shen; Shui-Hong Zhou; Qi Yu
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.